Abel Hall LLC’s MaxCyte MXCT Stock Holding History

Abel Hall LLC’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,110	Closed	-$8.51K	–	1041
2026 Q1	$8.51K	Buy	+12,110	New	+$11.3K	﹤0.01%	806

Other funds holding MXCT

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

KWMG LLC Overland Park, Kansas $1.38B AUM 33.35% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Abel Hall LLC's MXCT Position: Q2 2026 in Review

Abel Hall LLC sold out of MaxCyte (MXCT) in Q2 2026, closing a stake of 12,110 shares — an estimated $8.51K sold.

Abel Hall LLC first reported a position in MXCT in Q1 2026 and held it in 1 quarter. The position peaked at $8.51K in Q1 2026. 18 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Abel Hall LLC reported no remaining MaxCyte position as of Q2 2026 after selling out during the quarter.
Abel Hall LLC sold 12,110 MaxCyte shares in Q2 2026, an estimated $8.51K.
Abel Hall LLC first reported a position in MaxCyte in Q1 2026 and held it in 1 quarter.
Abel Hall LLC's MaxCyte position peaked at $8.51K in Q1 2026.
18 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.